3. RESULTS
A total of 16,285 AF patients were on liraglutide and 1,557,935 AF patients were not on liraglutide as of November 13, 2021. After propensity score matching, both cohorts had a size of 16,214 patients and their general characteristics can be seen in Table 1 .
AF patients on liraglutide were found to have a lower risk of all-cause mortality when compared to AF patients not on liraglutide (HR 0.67, 95% CI 0.631 - 0.711, p < 0.001). This was further supported with Kaplan-Meier analysis and log-rank test seen in Figure 1. It was found that survival probability was higher in patients with AF and liraglutide (66% vs. 63.5%, p < 0.001). There also appeared to be a lower risk for ischemic stroke, hemorrhagic stroke, acute heart failure episode, and acute coronary episode, although it did not reach statistical significance (Table 2 ).